Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$11.37 USD
-0.06 (-0.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.36 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AUPH 11.37 -0.06(-0.52%)
Will AUPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Other News for AUPH
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Reaches Analyst Target Price
Insider Sell: Greg Keenan Sells 20,000 Shares of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating
AUPH Analyst Rating Update: RBC Capital Raises Price Target | AUPH Stock News